Chinese Drug Firm Gains Global License to Develop Pfizer Anti-Cancer Drug
Di Ning
DATE:  Jan 26 2018
/ SOURCE:  Yicai
Chinese Drug Firm Gains Global License to Develop Pfizer Anti-Cancer Drug Chinese Drug Firm Gains Global License to Develop Pfizer Anti-Cancer Drug

(Yicai Global) Jan. 26 -- Chinese drug firm Suzhou Kintor Pharmaceuticals Inc. will exclusively develop, manufacture and commercialize a new antitumor drug worldwide after obtaining authorization from pharmaceutical giant Pfizer Inc.

The firm, based in China's eastern Jiangsu province, will conduct further research based on Pfizer's trials of the drug, which is already used for the treatment of liver cancer, to ascertain its effectiveness in treating other forms of the disease, Kintor said in a press briefing yesterday.

The project marks the second time that Pfizer has worked with Chinese pharmaceutical companies, after agreeing a licensing agreement with another Suzhou-based pharmaceutical firm PegBio Co. in December 2016 for the development of a diabetes drug.

International pharma firms often favor Chinese companies due to the huge market size in the country. The number of newly-diagnosed liver cancer patients in China each year accounts for nearly half of the global total, Shao Xianghong, head of Pfizer's China operations, said, adding that treatment for the disease currently in China is very scarce.

Founded in 2009, Kintor focuses on the research and development of prostate, breast and liver cancer drugs. The company secured C-series funding of CNY288 million (USD45 million) earlier in January.

Follow Yicai Global on
Keywords:   Suzhou Kintor Pharmaceuticals,Pfizer,Liver Cancer,PegBio,Authorization